33 Hayden Avenue
About Dicerna Pharmaceuticals
Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes. Our proprietary, next-generation technology, GalXC™, is a platform that uses the body’s natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health. We have qualified dozens of disease-associated genes in clinical indications where we believe an RNAi-based inhibitor may provide substantial benefit to patients, providing expansive therapeutic opportunities. Dicerna is advancing a growing pipeline of product candidates based on our GalXC platform to deliver transformative therapies to patients. OUR PEOPLE ARE OUR STRENGTH. Dicerna brings together talented experts in biology, chemistry, clinical science and medicine. With decades of scientific and technical experience focused on RNAi technology, our team has the knowledge and experience needed to discover, develop and commercialize safe and effective therapies for patients with serious unmet medical needs. Our purpose is clear: delivering life-changing therapies as efficiently as possible to meet the urgent needs of people living with debilitating genetic diseases.
Stock Exchange: NASDAQ
Stock Symbol: DRNA
At Dicerna, we interfere to silence genes, fight rare diseases, enhance health and advance science. The goal is to leverage our GalXC™ platform and strategic partnerships to get the drug to the patient as quickly as possible. Dicerna is dedicated to our patients and committed to breaking down barriers that slow progress in rare diseases. Dicerna promotes a “no walls” philosophy that fosters a collaborative culture where all employees are valued and respected. Dicerna interferes to help patients and change lives.
279 articles with Dicerna Pharmaceuticals
Dicerna™ Announces the Presentation of Updated Data Demonstrating Utility of its Lead Compound DCR-PHXC in Treating Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2)
PHYOX™1 Investigators Reported Potent, Durable Response in Phase 1 Study in Patients with PH1 and PH2 at German Society of Pediatric Nephrology 50th Annual Meeting
Dicerna™ Reports Fourth Quarter and Year Ended December 31, 2018 Financial Results and Provides Corporate Update
2018 was a Milestone Year for Dicerna Across a Variety of Fronts, Including Data Readouts for Primary Hyperoxaluria, Business Development Collaborations and a Successful Follow-On Offering
Dicerna to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call on March 11, 2019
Dicerna Pharmaceuticals, Inc. announced that the Company will release its fourth quarter and year end 2018 financial results after market close on Monday, March 11, 2019.
Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - March 1, 2019
Dicerna Pharmaceuticals, Inc. announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 238,000 shares of common stock to be distributed among six new employees, with a grant date of March 1, 2019.
Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference therapeutics, announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate overview at the following investor conferences in March
Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the addition of three industry veterans to the Company’s management team
— Regina DeTore Paglia Joins Company as Senior Vice President of Human Resources — Rebecca Peterson Hired as Head of Corporate Communications — Hardean E. Achneck, M.D., Joins as Vice President, Head of Medical Development
Dicerna Pharmaceuticals, Inc. announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 419,000 shares of common stock to be distributed among 14 new employees with a grant date of February 1, 2019.
Dicerna Announces Dosing of First Volunteer in Phase 1 Clinical Trial of DCR-HBVS Designed for the Treatment of Chronic Hepatitis B Virus
Clinical Proof-of-Concept Data Expected in Second Half of 2019
1/25/2019Movers and Shakers is BioSpace's weekly roundup of leadership appointments and changes within the biopharma world. Included this week are Genentech, Editas, Sage, Sangamo, and more.
J. Kevin Buchi Assumes Chairmanship Role and Industry Experts Marc Kozin and Anna Protopapas Join Dicerna Board
Dicerna Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) on January 2, 2019
Dicerna Pharmaceuticals, Inc. today announced that on January 2, 2019, the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 182,000 shares of common stock to be distributed among nine new employees, with a grant date of January 2, 2019 (the "Inducement Grant").
Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target from Research Collaboration with Dicerna
Boehringer Ingelheim and Dicerna Pharmaceuticals announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to a second hepatic disease target emerging from its research collaboration and license agreement with Dicerna.
Dicerna Pharmaceuticals, Inc. today announced that the Company will be added to the NASDAQ Biotechnology Index (Nasdaq:NBI) as part of the annual re-ranking, which will become effective prior to market open on Monday, December 24, 2018.
The companies entered into a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain.
Douglas M. Fambrough, Ph.D., president and chief executive officer, will host one-on-one investor meetings at Citi’s 2018 Global Healthcare Conference at the Lotte New York Palace Hotel in New York on Thursday, December 6, 2018.
Dicerna to Highlight Lead GalXC™ Pipeline Programs, Collaborations, and Advances to GalXC Technology Platform at R&D Day 2018
Dicerna Pharmaceuticals, Inc. will host an R&D Day today in New York City to discuss its pipeline of GalXC™-based RNAi therapeutic candidates.
Dicerna Pharmaceuticals, Inc. today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in three investor conferences in November.
Demonstrated Clinical POC for DCR-PHXC in Primary Hyperoxaluria and On Track to Initiate Registration Trial in Q1 2019
Dicerna Pharmaceuticals, Inc. today announced that the Company will release its third quarter 2018 financial results after market close on Monday, November 5, 2018.